Quick Take
BELLUS Health (BLU) has filed to raise gross proceeds of $60 million from a U.S. IPO, according to an F-10 registration statement.
The firm is developing therapeutics for chronic cough and other hypersensitization disorders.
BLU is in the middle of Phase 2 trials for its lead program but there is no existing investor support for the IPO.
Company & Technology
Laval, Canada-based BELLUS was founded in 2010 to focus on developing therapeutics for chronic cough and other chronic pruritus conditions associated with atopic dermatitis.
Management is headed by President, CEO